NO相关靶向药物治疗肝硬化门静脉高压的研究进展  

Research Progress of NO-related Targeted Drugs in Treatment of Cirrhotic Portal Hypertension

作　　者：庞晋荣 韩子岩[1] PANG Jinrong;HAN Ziyan(Department of Digestive Internal Medicine,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二医院消化内科,太原030001

出　　处：《医学综述》2022年第9期1789-1794,共6页Medical Recapitulate

摘　　要：门静脉高压是肝硬化常见的并发症,对患者预后具有显著不利影响。目前降低门静脉高压的基础药物仅有非选择性β受体阻滞剂(普萘洛尔)获批,但随着对门静脉高压形成机制认识的逐步深入,降低肝内阻力这一干预途径越来越受关注。而内皮型一氧化氮合酶/一氧化氮/可溶性鸟苷酸环化酶/环鸟苷酸通路的活化可抑制窦状血管收缩和毛细血管化,有效降低门静脉压力,因此一氧化氮相关靶向药物研究成为热点,如他汀类药物、奥贝胆酸、四氢生物蝶呤、抗氧化剂以及磷酸二酯酶5抑制剂等。这些药物在基础实验和临床研究中显示出广阔前景,可以为门静脉高压的治疗提供更多选择。As a common complication of liver cirrhosis,portal hypertension has a significant adverse effect on the prognosis of the patients.At present,only non-selectiveβ-blocker(propranolol)has been approved as the basic drug for the reduction of portal hypertension.However,with the gradual deepening understanding of the mechanism of portal hypertension,the intervention approach of reducing intrahepatic resistance has attracted more and more attention.Activation of endothelial nitric oxide synthase/nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate pathway can inhibit sinusoidal vasoconstriction and capillarization,which effectively reduces portal pressure.Therefore,research on nitric oxide-related targeted drugs has become a hot spot,such as statins,obecholic acid,tetrahydrobiopterin,antioxidants and phosphodiesterase type 5 inhibitor etc.These drugs are presenting broad prospects both in basic experiments and clinical researches,which are expected to provide more options to the treatment of portal hypertension.

关 键 词：门静脉高压 肝硬化 肝静脉压力梯度 一氧化氮 一氧化氮合酶 

分 类 号：R657.34[医药卫生—外科学] R575.2[医药卫生—临床医学]